https://www.selleckchem.com/products/bx471.html
In tier III are ranked various molecular alterations for which there is evidence of actionability in other tumors (IIIa) or that have similar functional impact in the same gene or pathway of a tier I alteration, without clinical data (IIIb). In tier IV are listed the molecular alterations for which only preclinical studies are available. In this review we report the most relevant molecular targets in BC, ordered pursuant to their pathway and classified in concordance with ESCAT. In this review we report the most relevant molecular targets
Like
Comment
Share
